BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Calliditas Therapeutics AB (publ):
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-09-11 7:42 pm Sale |
2024-09-02 | 13G | Calliditas Therapeutics AB (publ) CALT |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-6,260,311 (Position Closed) |
Filing |
| 2023-02-14 11:50 am Sale |
2022-12-31 | 13G | Calliditas Therapeutics AB (publ) CALT |
BIOTECHNOLOGY VALUE FUND L P | 6,260,311 10.500% |
-1,171,251 (-15.76%) |
Filing |
| 2020-11-12 5:11 pm Purchase |
2020-11-09 | 13G | Calliditas Therapeutics AB (publ) CALT |
BIOTECHNOLOGY VALUE FUND L P | 7,431,562 14.900% |
2,650,000 (+55.42%) |
Filing |
| 2020-06-08 10:27 am Purchase |
2020-06-05 | 13G | Calliditas Therapeutics AB (publ) CALT |
BIOTECHNOLOGY VALUE FUND L P | 4,781,562 9.700% |
4,781,562 (New Position) |
Filing |